

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 1 of 58

Atty. Dkt.: 2551-101




Fig. 1



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 2 of 58 Atty. Dkt.: 2551-101




Fig. 2



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 3 of 58 Atty. Dkt.: 2551-101




Fig. 3



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 4 of 58 Atty. Dkt.: 2551-101







Fig. 4

Anti-E1 levels in NON-responders to IFN treatment

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 5 of 58 Atty. Dkt.: 2551-101








weeks after start of treatment

Fig. 5



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 6 of 58 Atty. Dkt.: 2551-101








Anti-E1 levels in patients with COMPLETE response to IFN

SERIES 2

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 7 of 58 Atty. Dkt.: 2551-101








months after start of treatment Fig. 7




Anti-E1 levels in INCOMPLETE responders to IFN treatment

SERIES 2

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 8 of 58 Atty. Dkt.: 2551-101





months after start of treatment


Fig. 8



Anti-E2 levels in NON-RESPONDERS to IFN treatment

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 9 of 58

SN 08/928,757/Sheet 9 of 58 Atty. Dkt.: 2551-101



weeks after start of treatment Fig. 9



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 10 of 58 Atty. Dkt.: 2551-101





Fig. 10



Anti-E2 levels in INCOMPLETE responders to IFN treatment


Inventor: MAERTENS, et al. SN 08/928,757/Sheet 11 of 58 Atty. Dkt.: 2551-101






Inventor: MAERTENS, et al. SN 08/928,757/Sheet 12 of 58 Atty. Dkt.: 2551-101







સ

0.2

0.8

9.0

0.4

8

0.8

9.0

0.4

Fig. 13

8

0.2



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 14 of 58 Atty. Dkt.: 2551-101




Fig.14





Anti-E1 (epitope 1) levels in NON-RESPONDERS to IFN treatment

SERIES 1

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 15 of 58 Atty. Dkt.: 2551-101








weeks after start of treatment Fig.15





Anti-E1 (epitope 1) levels in RESPONDERS to IFN treatment

SERIES 1

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 16 of 58 Atty. Dkt.: 2551-101








weeks after start of treatment Fig.16





Anti-E1 (epitope 2) levels in NON-RESPONDERS to IFN treatment

SERIES 1

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 17 of 58 Atty. Dkt.: 2551-101








weeks after start of treatment Fig. 17



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 18 of 58 Atty. Dkt.: 2551-101



weeks after start of treatment Fig.18

Fig. 19

Fig. 20



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 21 of 58 Atty. Dkt.: 2551-101

### Fig. 21A

5' GGCATGCAAGCTTAATTAATT3' (SEQ ID NO 1)
3'ACGTCCGTACGTTCGAATTAATTAATCGA5' (SEQ ID NO 94)

#### SEQ ID NO 3 (HCCI9A)

#### SEQ ID NO 5 (HCCI10A)



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 22 of 58 Atty. Dkt.: 2551-101

### Fig. 21B

#### SEQ ID NO 7 (HCCI11A)

#### SEQ ID NO 9 (HCCl12A)

#### SEQ ID NO 11 (HCCI13A)



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 23 of 58 Attv. Dkt.: 2551-101

### Fig. 21C

### SEQ ID NO 13 (HCCI17A)

SEQ ID NO 15 (HCPr51)

ATGCCCGGTTGCTCTTTCTCTATCTT

SEQ ID NO 16 (HCPr52)
ATGTTGGGTAAGGTCATCGATACCCT

SEQ ID NO 17 (HCPr53)
CTATTAGGACCAGTTCATCATCATATCCCA

SEQ ID NO 18 (HCPr54)
CTATTACCAGTTCATCATCATATCCCA

SEQ ID NO 19 (HCPr107)
ATACGACGCCACGTCGATTCCCAGCTGTTCACCATC



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 24 of 58 Atty. Dkt.: 2551-101

Fig. 21D

SEQ ID NO 20 (HCPr108)
GATGGTGAACAGCTGGGAATCGACGTGGCGTCGTAT

### SEQ ID NO 21 (HCCI37)

### SEQ ID NO 23 (HCCI38)

#### SEQ ID NO 25 (HCC139)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 25 of 58 Atty. Dkt.: 2551-101

### Fig. 21E

### SEQ ID NO 27 (HCCl40)

#### SEQ ID NO 29 (HCC162)

ATGGGTAAGGTCATCGATACCCTTACGTGCGGATTCGCCGATCTCATGGGGTACATCC
CGCTCGTCGGCGCTCCCGTAGGAGGCGTCGCAAGAGCCCTTGCGCATGGCGTGAGGGC
CCTTGAAGACGGGATAAATTTCGCAACAGGGAATTTGCCCGGTTGCTCCTTTTCTATTT
TCCTTCTCGCTCTGTTCTCTTGCTTAATTCATCCAGCAGCTAGTCTAGAGTGGCGGAAT
ACGTCTGGCCTCTATGTCCTTACCAACGACTGTTCCAATAGCAGTATTGTGTACGAGGC
CGATGACGTTATTCTGCACACACCCGGCTGCATACCTTGTGTCCAGGACGCAATACA
TCCACGTGCTGGACCCCAGTGACACCTACAGTGGCAGTCAAGTACGTCGGAGCAACCA
CCGCTTCGATACGCAGTCATGTGGACCTATTAGTGGGCGCGGCCACGATGTGCTCTGC
GCTCTACGTGGGTGACATGTGTGGGGCTGTCTTCCTCGTGGGACAAGCCTTCACGTTCA
GACCTCGTCGCCATCAAACGGTCCAGACCTGTAACTGCTCGCTGTACCCAGGCCATCT
TTCAGGACATCGAATGGCTTGGGATATGATGATGAACTGGTAATAG



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 26 of 58

Atty. Dkt.: 2551-101

### Fig. 21F

SEQ ID NO 31 (HCCl63)

ATGGTAAGGTCATCGATACCCTAACGTGCGGATTCGCCGATCTCATGGGGTATATCC
CGCTCGTAGGCGGCCCCATTGGGGGCGTCGCAAGGGCTCTCGCACACGGTGTGAGGGT
CCTTGAGGACGGGGTAAACTATGCAACAGGGAATTTACCCGGTTGCTCTTTCTCTATCT
TTATTCTTGCTCTTCTCTCGTGTCTGACCGTTCCGGCCTCTGCAGTTCCCTACCGAAATG
CCTCTGGGATTTATCATGTTACCAATGATTGCCCAAACTCTTCCATAGTCTATGAGGCA
GATAACCTGATCCTACACGCACCTGGTTGCGTGCCTTGTGTCATGACAGGTAATGTGA
GTAGATGCTGGGTCCAAATTACCCCTACACTGTCAGCCCCGAGCCTCGGAGCAGTCAC
GGCTCCTCTTCGGAGAGCCGTTGACTACCTAGCGGGAGGGGCTGCCCTCTGCTCCGCG
TTATACGTAGGAGACGCGTGTGGGGCCACTATTCTTGGTAGGCCAAATGTTCACCTATA
GGCCTCGCCAGCACGCTACGGTGCAGAACTGCAACTGTTCCATTTACAGTGGCCATGT
TACCGGCCACCGGATGGCATGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 33 (HCPr109)
TGGGATATGATGATGAACTGGTC

SEQ ID NO 34 (HCPr72)
CTATTATGGTGGTAAKGCCARCARGAGCAGGAG

#### SEQ ID NO 35 (HCCL22A)



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 27 of 58 Atty. Dkt.: 2551-101

Fig. 21G

CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT
TAGGATGTACGTGGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG
AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG
TCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTCACCACCCTGCCGGCCCTATCCA
CCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTGCAATACCTGTACGGTGTAGG
GTCGGCGGTTGTCTCCCTTGTCATCAAATGGGAGTATGTCCTGTTGCTCTTCCTT
GGCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTGATAGCTCAAGCTGAG
GCCGCCTTAGAGAACCTGGTGGTCCTCAATGCGGCGGCCGTGGCCGGGGCGCATGGC
ACTCTTTCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAGGGCAGGCTGGTCCC
TGGTGCGGCATACGCCTTCTATGGCGTGTGCCCGCTGCTCCTTCTTCTTCCTTAC
CACCACGAGCTTATGCCTAGTAA

### SEQ ID NO 37 (HCCl41)

GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGCCCATTGGGGAGTCCTGGCGGG CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT TTGCCGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCCTCCGATACCA GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACAC AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC CTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAA CGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG 

### SEQ ID NO 39 (HCCl42)

GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGGGCCCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 28 of 58 Atty. Dkt.: 2551-101

### Fig. 21H

TTGCCGGCGTCGACGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCA GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACAC AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC CTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCG'AA CGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTG TCTACAACAGGTGATCGAGGGCAGACACCATCACCACCATCACTAATAG

### SEQ ID NO 41 (HCCl43)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC GACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTG ATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGTCTACAACAGAGTGG CAGAGCTTAATTAATTAG



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 29 of 58 Atty. Dkt.: 2551-101

### Fig. 21I

**SEQ ID NO 43 (HCCI44)** 

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC GACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTG ATTCTCAACACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGGTGAT CGAGGGCAGACACCATCACCACCATCACTAATAG

#### SEQ ID NO 45 (HCCL64)



1

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 30 of 58 Atty. Dkt.: 2551-101

Fig. 21J

### SEQ ID NO 47 (HCCl65)

AATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA TTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTAT GAGGCAGCGGACATGATCATGCACACCCCGGGTGCGTGCCCTGCGTTCGGGAGAAC AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG TCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTG TTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCA CCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGG CCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACG GCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTGGCGG GGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACTGGGC TAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGTGTCAG GAGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGC TCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACTGCCCT GAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAACACAAA TTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCG CTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGGCCCTA CTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGT CCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTGGTGT CCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAACACGCGG CCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGA CGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACACACCTTGACCTGCC



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 31 of 58 Atty. Dkt.: 2551-101

### Fig. 21K

### SEQ ID NO 49 (HCCl66)

ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCA CAGGACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGC GCAGGGCCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTCGCAAC CTCGTGGGAGGCGACAACCTATCCCCAAGGCTCGCCGACCCGAGGGTAGGGCCTGGG CTCAGCCCGGGTACCCTTGGCCCCTCTATGGCAATGAGGGCATGGGGTGGGCAGGATG GCTCCTGTCACCCCGCGGCTCTCGGCCTAGTTGGGGCCCTACAGACCCCCGGCGTAGG TCGCGTAATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGG GGTACATTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGG CGTCCGGGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCT TTCTCTATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAA GTGCGCAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTG GAACAACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCC AGCGTCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTT TCTGTTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTG TTCACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATC CCGGCCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTAC AACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTG GCGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACT · GGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGT GTCAGGAGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGG



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 32 of 58 Atty. Dkt.: 2551-101

### Fig. 21L

TCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACT GCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAAC ACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAA GTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGTATTGTACCCGCGTCTCAGGTGT GCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTT TGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAAC ACGCGGCCGCCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCA CCAAGACGTGTGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCAACACACCTTGA CCTGCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTAC CCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGGCGTGGAGC ACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACA GGGATAGATCAGAGCTTAGCCCGCTGCTGTCTACAACAGAGTGGCAGATACTGCC CTGTTCCTTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAAC ATCGTGGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCA AATGGGAGTATGTCCTGTTGCTCTTCCTTCTCTGGCAGACGCGCGCATCTGCGCCTGC TTATGGATGATGCTGATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCC GCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCG TGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA




Inventor: MAERTENS, et al. SN 08/928,757/Sheet 33 of 58 Atty. Dkt.: 2551-101

Fig. 22

## OD measured at 450 nm construct

Fraction volume dilution	39	40	62	63
	Type	Type	Type	Type
	1b	1b	3a	5a
START 23 ml 1/20 FLOW THROUGH 23 ml 1/20 1 0.4 ml 1/200 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	2.517	1.954	1.426	1.142
	0.087	0.085	0.176	0.120
	0.102	0.051	0.048	0.050
	0.396	0.550	0.090	0.067
	2.627	2.603	2.481	2.372
	3	2.967	3	2.694
	3	2.810	2.640	2.154
	2.694	2.499	1.359	1.561
	2.408	2.481	0.347	1.390
	2.176	1.970	1.624	0.865
	1.461	1.422	0.887	0.604
	1.286	0.926	0.543	0.519
	0.981	0.781	0.294	0.294
	0.812	0.650	0.249	0.199
	0.373	0.432	0.239	0.209
	0.653	0.371	0.145	0.184
	0.441	0.348	0.151	0.151
	0.321	0.374	0.098	0.106
	0.525	0.186	0.099	0.108
	0.351	0.171	0.083	0.090
	0.192	0.164	0.084	0.087





Inventor: MAERTENS, et al. SN 08/928,757/Sheet 35 of 58 Atty. Dkt.: 2551-101

# Fig. 24

OD measured at 450 nm construct

		Construct								
Fraction	volume	dilution	39	40	62	63				
, , , , , ,			Type	Type	Type	Type				
			1b	1b	3a	5a				
	050	4/200	0.072	0.130	0.096	0.051				
20	250 <i>µ</i> l	1/200	0.109	0.193	0.084	0.052				
21			0.109	0.249	0.172	0.052				
22			0.093	0.151	0.297	0.054				
23			0.080	0.266	0.438	0.056				
24			0.251	0.100	0.457	0.048				
25			3	1.649	0.722	0.066				
26			3	3	2.528	0.889				
27			3	3	3	2.345				
28			3 3	3	2.849	2.580				
29			2.227	1.921	1.424	1.333				
30			0.263	0.415	0.356	- 0.162				
31			0.071	0.172	0.154	0.064				
32 33			0.103	0.054	0.096	0.057				
	•		0.045	0.045	0.044	0.051				
34 35			0.043	0.047	0.045	0.046				
35 36			0.045	0.045	0.049	0.040				
36 37			0.045	0.047	0.046	0.048				
3 <i>1</i> 38			0.046	0.048	0.047	0.057				
39			0.045	0.048	0.050	0.057				
40			0.046	0.049	0.048	0.049				



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 36 of 58 Atty. Dkt.: 2551-101




Fig. 25



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 37 of 58 Atty. Dkt.: 2551-101




Fig. 26




Fig.27



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 38 of 58

Atty. Dkt.: 2551-101




Fig.28

M 1 2 3 4 5 6 Fig. 29

67 kD -

45 kD -

29 kD -

18 kD -

14 kD -

Lane 1: Crude Lysate

Lane 2: Flow through Lentil Chromatography

Lane 3: Wash with EMPIGEN Lentil Chromatography

Lane 4: Eluate Lentil Chromatography

Lane 5: Flow through during concentration lentil eluate

Lane 6: Pool of Elafter Size Exclusion Chromatography



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 39 of 58 Atty. Dkt.: 2551-101





Fig. 30

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 40 of 58 Atty. Dkt.: 2551-101

### NON - REDUCED

### Fig. 31A






Fig. 31B



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 41 of 58 Atty. Dkt.: 2551-101





Fig. 32



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 42 of 58 Atty. Dkt.: 2551-101

### SILVER STAIN OF PURIFIED E2




- 1. 30 mM IMIDAZOLE WASH Ni-IMAC
- 2. 0.5 ug E2

Fig.33



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 43 of 58 Atty. Dkt.: 2551-101



No.	Ret. (ml)	Peak start (ml)	Peak end (ml)	Dur (ml)	Area (ml*mAU)	Height (mAU)
1	-0.45	-0.46	-0.43	0.04	0.0976	4.579
2	1.55	0.75	3.26	2.51	796.4167	889.377
3	3.27	3.26	3.31	0.05	0.0067	0.224
4	3.33	3.32	3.33	0.02	0.0002	0.018

Total number of detected peaks = 4
Total Area above baseline = 0.796522 ml\*AU
Total area in evaluated peaks = 0.796521 ml\*AU
Ratio peak area / total area = 0.999999
Total peak duration = 2.613583 ml

Fig. 34

Inventor: MAERTENS, et al. SN 08/928,757/Sheet 44 of 58 Atty. Dkt.: 2551-101






Fig. 35A-1






Fig. 35A-2






Fig. 35A-3

### NS5 Ab LTR




Fig. 35A-4

### E1 Ab NR




Fig. 35A-5

### E1 Ab LTR




Fig. 35A-6



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 45 of 58 Atty. Dkt.: 2551-101




Fig. 35A-7




Fig. 35A-8



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 46 of 58 Atty. Dkt.: 2551-101




Fig. 35B-1




Fig. 35B-2




Fig. 35B-3




Fig. 35B-4




Fig. 35B-5




Fig. 35B-6



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 47 of 58 Atty. Dkt.: 2551-101

NS3 Ab NR

150100Start End 6 mo 12 mo

Fig. 35B-7




Fig. 35B-8



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 48 of 58 Atty. Dkt.: 2551-101

Fig. 36A

E1 Ab






Fig. 36B **E2 Ab** 








Inventor: MAERTENS, et al. SN 08/928,757/Sheet 50 of 58 Atty. Dkt.: 2551-101

Fig. 38

Relative Map Positions of anti-E2 monoclonal antibodies






Inventor: MAERTENS, et al. SN 08/928,757/Sheet 51 of 58 Atty. Dkt.: 2551-101

Fig.39

### PARTIAL DEGLYCOSYLATION OF HCV E1 ENVELOPE PROTEIN

ட	nm00 <del>1</del>
rse	um0 <del>1</del>
tida se I	ոա <sub>ե</sub>
oep IGa	um₽.0
(P)	um+0.0
g g	ոաՕ
<b>=</b>	nwg
ase )	nma.0
sid H c	nw <i>1</i> 09
yco	n <i>rl</i> 9
ogl E	n <i>rl</i> 9.0
pull	n <i>d</i> 0





Inventor: MAERTENS, et al. SN 08/928,757/Sheet 52 of 58 Atty. Dkt.: 2551-101

# PARTIAL TREATMENT OF HCV E2\E2S ENVELOPE PROTEINS BY PNGase F

	кDа	- 106	- 80	- 49.5	- 32.5
E2s (vvHCV-41)	U41.0 U41 Um10.0 Um1.0				
E2	- U410.0				00000
E2 (vvHCV-64)	U410.0 U41.0 U41.0 U41 Um10.0 Um1.0				
	K Da	106	80	49.5	32.5

Fig. 40




Inventor: MAERTENS, et al. SN 08/928,757/Sheet 53 of 58 Atty. Dkt.: 2551-101

E1Gly-2 E1Gly-3 E1Gly-5 E1Gly-4 E1Gly-6 E1Gly-1 五 Fig. 41 In Vitro Mutagenesis of HCV E1 glycoprotein @<del>|</del> 88 6 E ⊕-⊚-Bsp E I <u></u> 196 192 CORE ₽ T ATG 98 82 83 84 85 8



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 54 of 58 Atty. Dkt.: 2551-101

Fig. 42A In Vitro Mutagenesis of HCV E1 glycoprotein





Inventor: MAERTENS, et al. SN 08/928,757/Sheet 55 of 58 Atty. Dkt.: 2551-101

GPT-2

TKr-2

## 2. Overlap extension and nested PCR

a. Overlap extension

Fig. 42B


(1 min at 95°C; 1 min at 50°C; 1 min at 72°C) OVR-# antisense strand Nested PCR amplification (GPT-2 and TKr-2 primers) 2 cycles GLY-# sense strand

25 cycles (1 min at 95°C; 1 min at 55°C; 1 min at 72°C) Bam HI E1Gly-# EcoR I



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 56 of 58 Atty. Dkt.: 2551-101

Fig. 43 In Vitro Mutagenesis of HCV E1 glycoprotein





Inventor: MAERTENS, et al. SN 08/928,757/Sheet 57 of 58 Atty. Dkt.: 2551-101

HeLa cells

RK 13 cells

		1 3 4 5 6 7		2 3 4 5 6 8.		
80,0			_ 80,0			80,0
49.5			<b>— 49.5</b>		<del></del>	49.5
32.5	_		32.5		_	32.5
27.5			<b>— 27.5</b>		_	27.5
18.5			<b>— 18.5</b>			18.5

Fig. 44A




Fig.44B



Inventor: MAERTENS, et al. SN 08/928,757/Sheet 58 of 58 Atty. Dkt.: 2551-101



Fig.45




Fig.46